今日，赛诺菲（Sanofi）在今年美国血液学会（ASH）年会的摘要中公布了其潜在“first-in-class”口服BTK抑制剂rilzabrutinib在LUNA ...

The pharmaceutical company reported third-quarter earnings and sales that beat analysts’ expectations, boosted by ...

Sanofi announced that it has entered into exclusive negotiations with the US private equity firm Clayton, Dubilier & Rice (CD&R) to transfer around 50% controlling stake in Opella.

French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted ...

Sanofi entered into exclusive talks to sell a controlling stake in its consumer-healthcare business Opella to Clayton ...

在药品和健康市场不断变化的背景下，赛诺菲（Sanofi）近期的重大举动引发了业界的广泛关注。10月21日，赛诺菲宣布与美国私募股权公司Clayton Dubilier & Rice（CD&R）独家洽谈，计划出售其消费者健康部门Opella的50%控股权。这一消息无疑将为赛诺菲打开新的增长机遇，同时也为投资者和消费者的健康产品市场带来了新的思考。作为全球知名的生物制药公司，赛诺菲的每一步变动都可能对 ...

Jack Hidary, CEO of SandboxAQ, says the firm's partnership with Sanofi aims to drive biomarker discovery in clinical ...

Sanofi’s adoption of the Accumulus platform marks another move towards fit-for-purpose technology that ensures secure, real-time global regulatory connectivity. Many of the NRAs involved in the Sanofi ...

Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should spark some buyer’s delight. | Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should ...

Sanofi (SNY) has released an update. Sanofi’s Dupixent has received EU approval as the first treatment for children aged one to 11 with ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

Sanofi SAN-1.01%decrease; red down pointing triangle moved ahead with a plan to sell a controlling stake in its consumer-healthcare unit Opella to Clayton Dubilier & Rice, entering exclusive talks ...